FDA needs data on new Gardasil use

Merck hit another snag in its efforts to expand the market for its blockbuster cervical cancer vaccine Gardasil. The FDA told the company it wants additional data before deciding whether to approve its use in women ages 27 to 45. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.